Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Immune Dysfunction After Completion of Childhood Leukemia Therapy

Perkins, Joanna L. MD, MS; Harris, Anne MPH; Pozos, Tamara C. MD, PhD

Journal of Pediatric Hematology/Oncology: January 2017 - Volume 39 - Issue 1 - p 1–5
doi: 10.1097/MPH.0000000000000697
Original Articles

Background: Children with leukemia suffer immune dysfunction from their malignancy and chemotherapy. The immune system components most affected, the degree to which immune suppression occurs, and the duration of immunodeficiency are incompletely characterized. This study measures immunologic parameters following completion of therapy.

Methods: This is a prospective, single institution cohort study. Eligible children with acute myelogenous or acute lymphoblastic leukemia diagnosed between 1 and 21 years of age were enrolled at therapy completion. Immune parameters were assessed at the end of therapy and 6 months later: complete blood counts, immunoglobulin levels, quantitative lymphocyte subsets, mitogen-induced lymphocyte proliferation, natural killer cell function, and vaccine titers.

Results: Twenty patients were evaluated; 13 (65%) were female, 15 had acute lymphoblastic leukemia (75%). Mean age at diagnosis was 7.9 years. At end of therapy, all patients had some degree of immune dysfunction. At 6 months posttherapy, persistent abnormalities included: leukopenia (25%), neutropenia (15%), lymphopenia (5%), hypogammaglobulinemia (25%), one or more subtherapeutic vaccine titers (100%), abnormal lymphocyte subset levels (20%), decreased (15%), or absent (10%) natural killer cell function and abnormal lymphocyte proliferative responses (25%).

Conclusions: All patients had multiple abnormalities at end of therapy, and all patients had some degree of persistent immune dysfunction at 6 months after completion of therapy. Clinical implications of these laboratory abnormalities are currently unknown; longer term evaluations are ongoing. We demonstrate that survivors of childhood cancer have lasting quantitative and functional immunologic defects and may remain at risk for infectious complications after completion of therapy.

*Children’s Cancer and Blood Disorders Program, Children’s Hospitals and Clinics of Minnesota

Pediatric Infectious Diseases and Immunology, Children’s Hospitals and Clinics of Minnesota, Minneapolis, MN

Supported by 2010 Hope on Wheels Hyundai Scholar Award, Hyundai Motor America.

The authors declare no conflict of interest.

Reprints: Joanna L. Perkins, MD, MS, Children’s Hospitals and Clinics of Minnesota, 2530 Chicago Ave S., CSC-175, Minneapolis, MN 55404 (e-mail: joanna.perkins@childrensmn.org).

Received December 15, 2015

Accepted September 29, 2016

Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.